Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.46 |
| ▸ | PRKCA | P17252 | 2/20 | 0.46 |
| ▸ | GRK2 | P25098 | 2/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5657401 | 0.93 | GSK3B (0.59) | GSK3BMAPK1CASP1MAPK3CYP2C9 | |
| SCHEMBL4847310 | 0.92 | GSK3B (0.66) | GSK3BMAPK1CASP1MAPK3CYP2C9 | |
| SCHEMBL4856266 | 0.84 | CASP1 (0.69) | GSK3BMAPK1CASP1MAPK3CYP2C9 | |
| SCHEMBL13986976 | 0.84 | P2RX7 (0.63) | GSK3BMAPK1MAPK3P2RX7POLB | |
| SCHEMBL4848429 | 0.84 | GSK3B (0.67) | GSK3BMAPK1CASP1MAPK3CYP2C9 | |
| SCHEMBL4848467 | 0.83 | GSK3B (0.66) | GSK3BMAPK1CASP1CYP2C9ROCK2 | |
| SCHEMBL5231880 | 0.82 | GSK3B (0.81) | GSK3BMAPK1CASP1MAPK3ROCK2 | |
| SCHEMBL4856282 | 0.81 | GSK3B (0.69) | GSK3BMAPK1CASP1MAPK3CYP2C9 | |
| SCHEMBL4847300 | 0.81 | GSK3B (0.60) | GSK3BMAPK1CASP1MAPK3ROCK2 | |
| SCHEMBL4847289 | 0.81 | GSK3B (0.62) | GSK3BMAPK1CASP1MAPK3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | disclosed |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | C5, ADRA2C, ADRA1A | GSK3B 3708/4885MAPK1 3123/4885CASP1 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.